1. Home
  2. INVE vs CUE Comparison

INVE vs CUE Comparison

Compare INVE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INVE
  • CUE
  • Stock Information
  • Founded
  • INVE 1990
  • CUE 2014
  • Country
  • INVE United States
  • CUE United States
  • Employees
  • INVE N/A
  • CUE N/A
  • Industry
  • INVE Computer peripheral equipment
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • INVE Technology
  • CUE Health Care
  • Exchange
  • INVE Nasdaq
  • CUE Nasdaq
  • Market Cap
  • INVE 86.5M
  • CUE 91.9M
  • IPO Year
  • INVE 1997
  • CUE 2018
  • Fundamental
  • Price
  • INVE $3.48
  • CUE $1.26
  • Analyst Decision
  • INVE Strong Buy
  • CUE Strong Buy
  • Analyst Count
  • INVE 2
  • CUE 5
  • Target Price
  • INVE $7.25
  • CUE $5.00
  • AVG Volume (30 Days)
  • INVE 38.4K
  • CUE 285.1K
  • Earning Date
  • INVE 03-11-2025
  • CUE 03-10-2025
  • Dividend Yield
  • INVE N/A
  • CUE N/A
  • EPS Growth
  • INVE N/A
  • CUE N/A
  • EPS
  • INVE 3.10
  • CUE N/A
  • Revenue
  • INVE $104,217,000.00
  • CUE $9,532,000.00
  • Revenue This Year
  • INVE N/A
  • CUE $73.11
  • Revenue Next Year
  • INVE N/A
  • CUE $11.02
  • P/E Ratio
  • INVE $1.15
  • CUE N/A
  • Revenue Growth
  • INVE 70.57
  • CUE 149.53
  • 52 Week Low
  • INVE $2.95
  • CUE $0.45
  • 52 Week High
  • INVE $9.24
  • CUE $2.58
  • Technical
  • Relative Strength Index (RSI)
  • INVE 43.25
  • CUE 49.50
  • Support Level
  • INVE $3.50
  • CUE $1.27
  • Resistance Level
  • INVE $3.82
  • CUE $1.50
  • Average True Range (ATR)
  • INVE 0.18
  • CUE 0.12
  • MACD
  • INVE -0.01
  • CUE -0.01
  • Stochastic Oscillator
  • INVE 21.82
  • CUE 53.73

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: